BATF2

Summary

BATF2 (basic leucine zipper ATF-like transcription factor 2, HGNC:25163) is a protein-coding gene on chromosome 11q13.1, encoding Basic leucine zipper transcriptional factor ATF-like 2 (Q8N1L9). AP-1 family transcription factor that controls the differentiation of lineage-specific cells in the immune system.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in defense response to protozoan; myeloid dendritic cell differentiation; and regulation of transcription by RNA polymerase II. Part of RNA polymerase II transcription regulator complex.

Source: NCBI Gene 116071 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 50 total
• MANE Select transcript: NM_138456

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25163
Approved symbol	BATF2
Name	basic leucine zipper ATF-like transcription factor 2
Location	11q13.1
Locus type	gene with protein product
Status	Approved
Aliases	MGC20410, SARI
Ensembl gene	ENSG00000168062
Ensembl biotype	protein_coding
OMIM	614983
Entrez	116071

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 retained_intron

ENST00000301887, ENST00000435842, ENST00000527454, ENST00000527716, ENST00000534177

RefSeq mRNA: 3 — MANE Select: NM_138456 NM_001300807, NM_001300808, NM_138456

CCDS: CCDS73317, CCDS76429, CCDS8087

Canonical transcript exons

ENST00000301887 — 3 exons

Exon	Start	End
ENSE00001408542	64996876	64996971
ENSE00001414327	64994448	64994549
ENSE00002151448	64987945	64989812

Expression profiles

Bgee: expression breadth ubiquitous, 179 present calls, max score 91.95.

FANTOM5 (CAGE): breadth broad, TPM avg 4.5972 / max 987.8589, expressed in 615 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
120516	4.3061	543
120515	0.2911	144

Top tissues by expression

238 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	91.95	silver quality
oocyte	CL:0000023	88.67	gold quality
mucosa of transverse colon	UBERON:0004991	83.75	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.74	gold quality
secondary oocyte	CL:0000655	81.06	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.44	gold quality
spleen	UBERON:0002106	80.19	gold quality
vermiform appendix	UBERON:0001154	79.04	gold quality
apex of heart	UBERON:0002098	78.52	gold quality
body of pancreas	UBERON:0001150	77.63	gold quality
transverse colon	UBERON:0001157	77.50	gold quality
ileal mucosa	UBERON:0000331	77.28	gold quality
granulocyte	CL:0000094	76.90	gold quality
nasal cavity epithelium	UBERON:0005384	76.68	silver quality
endothelial cell	CL:0000115	76.44	silver quality
rectum	UBERON:0001052	76.28	gold quality
caecum	UBERON:0001153	76.24	gold quality
kidney epithelium	UBERON:0004819	75.38	gold quality
leukocyte	CL:0000738	75.35	gold quality
monocyte	CL:0000576	75.29	gold quality
pancreas	UBERON:0001264	74.75	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	74.62	gold quality
colon	UBERON:0001155	74.49	gold quality
large intestine	UBERON:0000059	74.44	gold quality
small intestine	UBERON:0002108	74.26	gold quality
small intestine Peyer’s patch	UBERON:0003454	74.17	gold quality
duodenum	UBERON:0002114	74.08	gold quality
intestine	UBERON:0000160	73.99	gold quality
right lobe of liver	UBERON:0001114	73.79	gold quality
hindlimb stylopod muscle	UBERON:0004252	73.71	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-7052	no	47.17
E-ANND-3	no	1.99

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
CCNA2

Upstream regulators (CollecTRI, top): CTCF

miRNA regulators (miRDB)

35 targeting BATF2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-377-5P	99.70	65.28	712
HSA-MIR-6086	99.70	65.38	699
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-4688	99.48	64.68	828
HSA-MIR-4666A-5P	99.41	69.72	1887
HSA-MIR-3152-3P	99.10	66.35	678
HSA-MIR-661	99.09	65.94	2062
HSA-MIR-877-3P	99.09	68.10	1637
HSA-MIR-4796-3P	99.08	68.38	1681
HSA-MIR-1294	98.91	69.26	1030
HSA-MIR-9986	98.91	69.28	1024
HSA-MIR-455-5P	98.74	67.31	795
HSA-MIR-655-5P	98.74	65.93	888
HSA-MIR-6804-5P	98.39	65.77	1084
HSA-MIR-6884-3P	98.05	65.32	750
HSA-MIR-665	97.60	65.64	1781
HSA-MIR-4640-5P	97.42	66.33	1543
HSA-MIR-194-3P	97.36	65.96	1027
HSA-MIR-4288	97.11	67.23	1636
HSA-MIR-4474-3P	96.97	65.87	870
HSA-MIR-6762-5P	96.55	64.62	972
HSA-MIR-6845-5P	96.55	64.65	969
HSA-MIR-342-3P	96.44	67.48	1344
HSA-MIR-759	96.16	66.77	873

Literature-anchored findings (GeneRIF, showing 34)

• Decreased expression of BATF2 is associated with hepatocellular carcinoma. (PMID:20473897)
• Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1. (PMID:20531301)
• BCR-ABL mediates the down-regulation of SARI mRNA expression in K562 cells. (PMID:21867603)
• Data suggest that SARI as a potential therapeutic target in CML. (PMID:21892628)
• Loss of SARI expression initiates epithelial-to-mesenchymal transition (EMT), which is visualized by repression of E-cadherin and up-regulation of vimentin in lung adenocarcinoma cell lines and in clinical lung adenocarcinoma specimens. (PMID:23049725)
• SARI expression may predict a poor prognosis in non-small cell lung patients, and SARI may serve as a prognostic biomarker and potential therapeutic target for lung cancer. (PMID:24133583)
• BATF2 plays a tumor-suppressor role in the development of oral tongue squamous cell carcinoma and BATF2 may serve as a prognostic biomarker and potential therapeutic target for this disease. (PMID:24252932)
• MDA-7/IL-24 has a role in cancer-specific apoptosis through SARI induction (PMID:24282278)
• these novel findings suggest that BATF2, a tumor suppressor gene, is a potent negative regulator of HGF/MET signaling in colorectal cancer (PMID:25762344)
• these findings indicate that BATF2 status could be served as a potential biomarker to predict prognosis in colorectal cancer (PMID:26022579)
• In conclusion, as a tumor suppressor, BATF2 serves as a prognostic biomarker of esophageal squamous cell carcinoma and it may be a potential therapeutic target for ESCC treatment. (PMID:26135942)
• Suggest that SARI might play an important role in the occurrence and development of prostate cancer. IFN-beta might inhibit the growth of prostate cancer and promote cellular apoptosis by inducing the expression of SARI. (PMID:26339361)
• Batf2 has a role in infectious diseases and cancer (PMID:26376615)
• Results demonstrate that SARI is a novel target gene of glucocorticoid receptor, and the upregulation of SARI plays an important role in dexamethasone’s killing effect on B lymphoma cells. (PMID:26808579)
• BATF2 may exert selective pressure on the recombination machinery via a repetitive motif-based mechanism for the maintenance of heterochromatin stability. (PMID:26977016)
• BATF2 gene was modulated after treatment with zebularine and was a poor prognostic marker, since its low levels were correlated with relapse and a poor prognosis for medulloblastoma patients. (PMID:27785591)
• Gain- and loss-of-function studies uncovered a role for Batf2 in myeloid differentiation in both murine and human systems. We thus demonstrate that chronic infection can deplete HSPCs and identify BATF2 as a mediator of infection-induced HSPC terminal differentiation (PMID:27926863)
• Our findings expanded the understanding of the role of BATF2 in tumors, and also suggested a potential of using BATF2 as a therapeutic target to hinder bevacizumab induced epithelial-mesenchymal transition in glioblastoma. (PMID:28739720)
• BATF2 gene expression is associated with tuberculosis in the HIV infected patients. (PMID:29764370)
• BATF2 role in the multidrug resistance of human gastric cancer cells and the regulation of the Wnt/beta-catenin signaling. (PMID:31140101)
• BATF2 was overexpressed in tissues from patients with non-responsive gastric cancer (GC) and the vincristine resistance cell line, SGC7901/VCR, while levels of c-Fos and c-Jun were reduced. AP-1 down-regulation by BATF2 overexpression or AP-1 knockdown can inhibit drug resistance in GC cells. These findings suggest that BATF2 inhibits DR in vincristine resistance GC cell line by down-regulating AP-1 expression. (PMID:31549215)
• SARI prevents ocular angiogenesis and inflammation in mice. (PMID:32119762)
• miRNA-765 mediates multidrug resistance via targeting BATF2 in gastric cancer cells. (PMID:32166887)
• m(6)A modification-mediated BATF2 acts as a tumor suppressor in gastric cancer through inhibition of ERK signaling. (PMID:32650804)
• BATF2 expression as a novel marker for invasive phenotype in malignant melanoma. (PMID:32696470)
• BATF2 prevents glioblastoma multiforme progression by inhibiting recruitment of myeloid-derived suppressor cells. (PMID:33452462)
• BATF2 balances the T cell-mediated immune response of CADM with an anti-MDA5 autoantibody. (PMID:33740622)
• Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer. (PMID:34565331)
• SARI inhibits growth and reduces survival of oral squamous cell carcinomas (OSCC) by inducing endoplasmic reticulum stress. (PMID:34774620)
• m6A modification-mediated BATF2 suppresses metastasis and angiogenesis of tongue squamous cell carcinoma through inhibiting VEGFA. (PMID:35949109)
• Loss of the Immunomodulatory Transcription Factor BATF2 in Humans Is Associated with a Neurological Phenotype. (PMID:36672163)
• Nuclear export of BATF2 enhances colorectal cancer proliferation through binding to CRM1. (PMID:37151195)
• BATF2 inhibits PD-L1 expression and regulates CD8+ T-cell infiltration in non-small cell lung cancer. (PMID:37777155)
• Exosomal miR-361-3p promotes the viability of breast cancer cells by targeting ETV7 and BATF2 to upregulate the PAI-1/ERK pathway. (PMID:38282047)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	fosaa	ENSDARG00000040135
danio_rerio	si:ch211-153j24.3	ENSDARG00000068428
mus_musculus	Batf2	ENSMUSG00000039699
rattus_norvegicus	Batf2	ENSRNOG00000021018
drosophila_melanogaster	Atf3	FBGN0028550

Paralogs (8): FOSL2 (ENSG00000075426), BATF3 (ENSG00000123685), FOSB (ENSG00000125740), JDP2 (ENSG00000140044), BATF (ENSG00000156127), ATF3 (ENSG00000162772), FOS (ENSG00000170345), FOSL1 (ENSG00000175592)

Protein

Protein identifiers

Basic leucine zipper transcriptional factor ATF-like 2 — Q8N1L9 (reviewed: Q8N1L9)

Alternative names: Suppressor of AP-1 regulated by IFN

All UniProt accessions (3): B4DV37, E9PJ73, Q8N1L9

UniProt curated annotations — full annotation on UniProt →

Function. AP-1 family transcription factor that controls the differentiation of lineage-specific cells in the immune system. Following infection, participates in the differentiation of CD8(+) thymic conventional dendritic cells in the immune system. Acts via the formation of a heterodimer with JUN family proteins that recognizes and binds DNA sequence 5’-TGA[CG]TCA-3’ and regulates expression of target genes. Selectively suppresses CCN1 transcription and hence blocks the downstream cell proliferation signals produced by CCN1 and inhibits CCN1-induced anchorage-independent growth and invasion in several cancer types, such as breast cancer, malignant glioma and metastatic melanoma. Possibly acts by interfering with AP-1 binding to CCN1 promoter.

Subunit / interactions. Heterodimer; heterodimerizes with JUN family proteins.

Subcellular location. Nucleus.

Induction. By type I interferon. Down-regulated in most hepatocellular carcinoma tumorous tissues (at protein level).

Similarity. Belongs to the bZIP family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N1L9-1	1	yes
Q8N1L9-2	2

RefSeq proteins (3): NP_001287736, NP_001287737, NP_612465* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000837	AP-1	Family
IPR004827	bZIP	Domain
IPR046347	bZIP_sf	Homologous_superfamily

Pfam: PF00170

UniProt features (11 total): region of interest 5, compositionally biased region 2, chain 1, domain 1, sequence variant 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N1L9-F1	62.92	0.27

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 200 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_DENDRITIC_CELL_DIFFERENTIATION, GOZGIT_ESR1_TARGETS_DN, GOBP_MYELOID_LEUKOCYTE_DIFFERENTIATION, USF_C, chr11q13, IRF7_01, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, FOSTER_TOLERANT_MACROPHAGE_UP, GOBP_MYELOID_LEUKOCYTE_ACTIVATION, GOBP_RESPONSE_TO_PROTOZOAN, IRF_Q6, NRF2_01, P53_DECAMER_Q2, ISRE_01

GO Biological Process (6): regulation of transcription by RNA polymerase II (GO:0006357), defense response to protozoan (GO:0042832), myeloid dendritic cell differentiation (GO:0043011), integrated stress response signaling (GO:0140467), regulation of DNA-templated transcription (GO:0006355), cell differentiation (GO:0030154)

GO Molecular Function (5): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), protein binding (GO:0005515)

GO Cellular Component (3): chromatin (GO:0000785), nucleus (GO:0005634), RNA polymerase II transcription regulator complex (GO:0090575)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
transcription by RNA polymerase II	1
response to protozoan	1
defense response to other organism	1
myeloid dendritic cell activation	1
myeloid leukocyte differentiation	1
dendritic cell differentiation	1
cellular response to stress	1
intracellular signaling cassette	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cellular developmental process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
nucleic acid binding	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
binding	1
chromosome	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1
transcription regulator complex	1
nuclear protein-containing complex	1

Protein interactions and networks

STRING

1180 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
BATF2	JUN	P05412	704
BATF2	IRF1	P10914	621
BATF2	ATF6B	Q99941	597
BATF2	ANKRD22	Q5VYY1	575
BATF2	ATF5	Q9Y2D1	554
BATF2	DAZAP2	Q15038	487
BATF2	GBP5	Q96PP8	456
BATF2	ATF3	P18847	447
BATF2	CP	P00450	433
BATF2	SCARF1	Q14162	428
BATF2	ETV7	Q9Y603	428
BATF2	FCGR1BP	Q92637	417
BATF2	ATF4	P18848	413
BATF2	SEC13	P55735	397
BATF2	IRF8	Q02556	396

IntAct

63 interactions, top by confidence:

A	B	Type	Score
JUNB	BATF2	psi-mi:“MI:0407”(direct interaction)	0.680
JUNB	BATF2	psi-mi:“MI:0915”(physical association)	0.680
BATF2	JUNB	psi-mi:“MI:0915”(physical association)	0.680
JUNB	BATF2	psi-mi:“MI:0403”(colocalization)	0.680
BATF2	DAZAP2	psi-mi:“MI:0915”(physical association)	0.620
DAZAP2	BATF2	psi-mi:“MI:0915”(physical association)	0.620
BATF2	SPAG8	psi-mi:“MI:0915”(physical association)	0.560
PROP1	BATF2	psi-mi:“MI:0915”(physical association)	0.560
VENTX	BATF2	psi-mi:“MI:0915”(physical association)	0.560
BATF2	YTHDF1	psi-mi:“MI:0915”(physical association)	0.560
HOXA1	BATF2	psi-mi:“MI:0915”(physical association)	0.560
KRT34	BATF2	psi-mi:“MI:0915”(physical association)	0.560
BATF2	GPSM3	psi-mi:“MI:0915”(physical association)	0.560
FOXH1	BATF2	psi-mi:“MI:0915”(physical association)	0.560
FOXI1	BATF2	psi-mi:“MI:0915”(physical association)	0.560
MKRN3	BATF2	psi-mi:“MI:0915”(physical association)	0.560
BATF2	PPP1R16A	psi-mi:“MI:0915”(physical association)	0.560
BATF2	DDIT3	psi-mi:“MI:0407”(direct interaction)	0.440
BATF2	CEBPG	psi-mi:“MI:0407”(direct interaction)	0.440
CEBPA	BATF2	psi-mi:“MI:0407”(direct interaction)	0.440
BATF2	JUN	psi-mi:“MI:0407”(direct interaction)	0.440
BATF2	ATF4	psi-mi:“MI:0407”(direct interaction)	0.440
DDIT3	BATF2	psi-mi:“MI:0407”(direct interaction)	0.440
CEBPG	BATF2	psi-mi:“MI:0407”(direct interaction)	0.440
CEBPE	BATF2	psi-mi:“MI:0407”(direct interaction)	0.440
DBP	BATF2	psi-mi:“MI:0407”(direct interaction)	0.440
HLF	BATF2	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (38): BATF2 (Two-hybrid), BATF2 (Two-hybrid), BATF2 (Two-hybrid), BATF2 (Two-hybrid), BATF2 (Two-hybrid), BATF2 (Two-hybrid), BATF2 (Two-hybrid), BATF2 (Two-hybrid), FOXI1 (Two-hybrid), PROP1 (Two-hybrid), MKRN3 (Two-hybrid), GPSM3 (Two-hybrid), BATF2 (Affinity Capture-RNA), BATF2 (Two-hybrid), BATF2 (Two-hybrid)

ESM2 similar proteins: A0A5F9ZHS7, A1YGK1, A2T7E6, A8MZG2, O08574, O43593, O60393, O75593, O88621, O95231, P0C1T1, P0CG20, P20428, P97609, Q04667, Q17QR5, Q2KIS6, Q2M1V0, Q2T9Q7, Q32LE6, Q497V6, Q5JUK2, Q5M844, Q5RJB0, Q5TGS1, Q61645, Q61657, Q6ZMY3, Q6ZN32, Q6ZNG2, Q7RTU1, Q8BZW2, Q8CGW9, Q8IWN7, Q8IXT2, Q8IZ20, Q8N1L9, Q8N7G0, Q8N944, Q8N9Y4

Diamond homologs: A1L2X1, D4A7E1, E1BD44, F1QW76, F7EMX9, O02761, O35284, O77628, O88479, O97930, P01100, P01101, P01102, P11939, P12841, P18847, P23050, P29176, P29596, P53450, Q16520, Q2KII1, Q56TN0, Q56TT7, Q60765, Q6DGM8, Q8HZP6, Q8N1L9, Q8WYK2, Q91496, Q9Z2Q8, B4PPK2, P79702, P97876, Q9D275, Q9NR55, Q8R1H8

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 29 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Cellular responses to stress	5	9.7×	6e-03
Cellular responses to stimuli	5	8.3×	8e-03

GO biological processes:

GO term	Partners	Fold	FDR
integrated stress response signaling	7	182.0×	8e-13
liver development	5	41.1×	1e-05
regulation of cell cycle	5	13.8×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

50 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	45
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

551 predictions. Top by Δscore:

Variant	Effect	Δscore
11:64994442:CCACA:C	donor_loss	1.0000
11:64994443:CACAC:C	donor_loss	1.0000
11:64994444:ACACC:A	donor_loss	1.0000
11:64994446:A:AT	donor_loss	1.0000
11:64994447:CC:C	donor_loss	1.0000
11:64994548:TC:T	acceptor_gain	1.0000
11:64994548:TCC:T	acceptor_loss	1.0000
11:64994549:CC:C	acceptor_gain	1.0000
11:64994549:CCTG:C	acceptor_loss	1.0000
11:64994550:C:CC	acceptor_gain	1.0000
11:64994550:C:CG	acceptor_loss	1.0000
11:64994551:T:C	acceptor_loss	1.0000
11:64989808:TGCTG:T	acceptor_gain	0.9900
11:64989810:CTG:C	acceptor_gain	0.9900
11:64989811:TG:T	acceptor_gain	0.9900
11:64989813:C:CC	acceptor_gain	0.9900
11:64993471:A:AC	donor_gain	0.9900
11:64993472:C:CC	donor_gain	0.9900
11:64994464:G:A	donor_gain	0.9900
11:64994545:GGGTC:G	acceptor_gain	0.9900
11:64994546:GGTC:G	acceptor_gain	0.9900
11:64994547:GTC:G	acceptor_gain	0.9900
11:64996874:A:AC	donor_gain	0.9900
11:64996875:C:CA	donor_gain	0.9900
11:64996875:CT:C	donor_gain	0.9900
11:64996875:CTGT:C	donor_gain	0.9900
11:64989812:GC:G	acceptor_loss	0.9800
11:64989814:T:C	acceptor_loss	0.9800
11:64993546:C:CC	acceptor_gain	0.9800
11:64996868:GTACT:G	donor_loss	0.9800

AlphaMissense

1744 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:64994453:G:C	H46D	0.992
11:64994465:C:G	A42P	0.989
11:64989778:A:G	L59P	0.987
11:64989757:A:G	L66P	0.986
11:64994497:G:T	A31D	0.985
11:64994455:A:G	L45P	0.984
11:64994491:C:G	R33P	0.984
11:64994485:C:G	R35P	0.982
11:64989766:A:G	I63T	0.981
11:64994487:G:C	S34R	0.981
11:64994487:G:T	S34R	0.981
11:64994489:T:G	S34R	0.981
11:64994506:C:G	R28P	0.981
11:64994486:G:C	R35G	0.980
11:64989737:A:G	W73R	0.979
11:64989737:A:T	W73R	0.979
11:64989799:A:G	L52P	0.979
11:64989745:A:G	L70P	0.978
11:64994501:C:G	A30P	0.978
11:64994466:C:A	K41N	0.977
11:64994466:C:G	K41N	0.977
11:64994453:G:T	H46N	0.976
11:64994498:C:G	A31P	0.976
11:64989775:C:G	R60P	0.975
11:64994451:G:C	H46Q	0.972
11:64994451:G:T	H46Q	0.972
11:64994520:C:A	K23N	0.971
11:64994520:C:G	K23N	0.971
11:64989724:A:G	L77P	0.967
11:64994510:T:C	N27D	0.967

dbSNP variants (sampled 300 via entrez): RS1000238066 (11:64992338 A>G), RS1001075892 (11:64992096 A>G), RS1001486181 (11:64991807 G>A), RS1002077475 (11:64992778 C>T), RS1002476335 (11:64992821 A>T), RS1002511709 (11:64992415 C>A), RS1002534280 (11:64987994 T>C,G), RS1003139308 (11:64996196 G>A,T), RS1003462979 (11:64994633 C>G,T), RS1003481644 (11:64994814 A>T), RS1003497305 (11:64988967 C>T), RS1003826280 (11:64987748 G>C,T), RS1004191603 (11:64995414 A>C), RS1004222727 (11:64995034 A>C), RS1004452577 (11:64988107 G>A)

Disease associations

OMIM: gene MIM:614983 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Nickel	increases expression	2
Tretinoin	increases expression	2
fluorene-9-bisphenol	decreases expression	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
pirinixic acid	increases expression, affects binding, increases activity	1
beta-lapachone	increases expression	1
butyraldehyde	increases expression	1
ferrous chloride	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
pentanal	increases expression	1
abrine	decreases expression	1
Acetaminophen	decreases expression	1
Aldehydes	increases expression	1
Camptothecin	increases expression	1
Doxorubicin	decreases expression	1
Lipopolysaccharides	increases expression, affects response to substance	1
Silicon Dioxide	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	decreases expression, increases methylation	1
Aflatoxin B1	increases methylation	1
Antirheumatic Agents	decreases expression	1
Copper Sulfate	decreases expression	1
S-Nitrosoglutathione	increases expression	1
Particulate Matter	increases expression	1

Cellosaurus cell lines

5 cell lines: 4 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1EN	Abcam A-549 BATF2 KO 1	Cancer cell line	Male
CVCL_B2M7	Abcam A-549 BATF2 KO 2	Cancer cell line	Male
CVCL_D7G6	Ubigene HEK293T BATF2 KO	Transformed cell line	Female
CVCL_E1RS	HAP1 BATF2 (-) 1	Cancer cell line	Male
CVCL_E1RT	HAP1 BATF2 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.